Clinical Trials Browser

Interventional × BI 2536 × Gastrointestinal × Clear all

NCT00710710 2022-05-04

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Phase 2 Completed

89 enrolled 20 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02215044 2014-08-13

Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms